Cleared Traditional

Evidence MultiSTAT DOA Urine MultiPlex, Evidence MultiSTAT (K220451) - FDA 510(k) Clearance

Class II Chemistry device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K220451 · Randox Laboratories Limited · Chemistry device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Oct 2023
Decision
595d
Days
Class 2
Risk

K220451 is an FDA 510(k) clearance for the Evidence MultiSTAT DOA Urine MultiPlex, Evidence MultiSTAT. Classified as Enzyme Immunoassay, Opiates (product code DJG), Class II - Special Controls.

Submitted by Randox Laboratories Limited (Crumlin, GB). The FDA issued a Cleared decision on October 5, 2023 after a review of 595 days - an unusually long review period, suggesting complex equivalence evaluation.

This device falls under the Chemistry FDA review panel, regulated under 21 CFR 862.3650 - the FDA in vitro diagnostics and chemistry framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: High-complexity regulatory submission. Elevated predicate reliance profile. The extended review timeline suggests the FDA required additional documentation before confirming substantial equivalence - a pattern common in complex or first-of-kind Chemistry submissions.

View all Randox Laboratories Limited devices

Submission Details

510(k) Number K220451 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received February 17, 2022
Decision Date October 05, 2023
Days to Decision 595 days
Submission Type Traditional
Review Panel Chemistry (CH)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
507d slower than avg
Panel avg: 88d · This submission: 595d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code DJG Enzyme Immunoassay, Opiates
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.3650
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Chemistry devices follow this clearance model.

Regulatory Peers - DJG Enzyme Immunoassay, Opiates

All 87
Devices cleared under the same product code (DJG) and FDA review panel - the closest regulatory comparables to K220451.
Chemtrue® Drug Screen Fentanyl/Tramadol Cup Test, Chemtrue® Drug Screen Fentanyl/Tramadol Dip Card Test, Chemtrue® Multi-Panel Drug Screen Cup Test, Chemtrue® Multi-Panel Drug Screen Dip Card Test
K232736 · Chemtron Biotech, Inc. · Dec 2023
Dochek® Multi-Drug Urine Test Cup Rx, Dochek® Multi-Drug Urine Test Cup
K232659 · Guangzhou Decheng Biotechnology Co., Ltd. · Dec 2023
ARK Hydrocodone Assay
K231752 · ARK Diagnostics, Inc. · Nov 2023
Evidence MultiSTAT DOA Urine MultiPlex
K221550 · Randox Laboratories Limited · Oct 2023
CEDIA Heroin Metabolite (6-AM) Assay
K231007 · Microgenics Corporation · Sep 2023
AllTest Fentanyl Rapid Test (Urine)
K231698 · Hangzhou AllTest Biotech Co., Ltd. · Jul 2023